187 related articles for article (PubMed ID: 27026573)
21. The clinical spectrum of SMA-PME and in vitro normalization of its cellular ceramide profile.
Lee MM; McDowell GSV; De Vivo DC; Friedman D; Berkovic SF; Spanou M; Dinopoulos A; Grand K; Sanchez-Lara PA; Allen-Sharpley M; Warman-Chardon J; Solyom A; Levade T; Schuchman EH; Bennett SAL; Dyment DA; Pearson TS
Ann Clin Transl Neurol; 2022 Dec; 9(12):1941-1952. PubMed ID: 36325744
[TBL] [Abstract][Full Text] [Related]
22. Acid ceramidase deficiency: Farber disease and SMA-PME.
Yu FPS; Amintas S; Levade T; Medin JA
Orphanet J Rare Dis; 2018 Jul; 13(1):121. PubMed ID: 30029679
[TBL] [Abstract][Full Text] [Related]
23. Spinal muscular atrophy-like phenotype in a mouse model of acid ceramidase deficiency.
Nagree MS; Rybova J; Kleynerman A; Ahrenhoerster CJ; Saville JT; Xu T; Bachochin M; McKillop WM; Lawlor MW; Pshezhetsky AV; Isaeva O; Budde MD; Fuller M; Medin JA
Commun Biol; 2023 May; 6(1):560. PubMed ID: 37231125
[TBL] [Abstract][Full Text] [Related]
24. Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene.
Alves MQ; Le Trionnaire E; Ribeiro I; Carpentier S; Harzer K; Levade T; Ribeiro MG
Mol Genet Metab; 2013 Jul; 109(3):276-81. PubMed ID: 23707712
[TBL] [Abstract][Full Text] [Related]
25. Whole-transcriptome sequencing in blood provides a diagnosis of spinal muscular atrophy with progressive myoclonic epilepsy.
Kernohan KD; Frésard L; Zappala Z; Hartley T; Smith KS; Wagner J; Xu H; McBride A; Bourque PR; Consortium CRC; Bennett SAL; Dyment DA; Boycott KM; Montgomery SB; Warman Chardon J
Hum Mutat; 2017 Jun; 38(6):611-614. PubMed ID: 28251733
[TBL] [Abstract][Full Text] [Related]
26. The molecular medicine of acid ceramidase.
Frohbergh M; He X; Schuchman EH
Biol Chem; 2015 Jun; 396(6-7):759-65. PubMed ID: 25938220
[TBL] [Abstract][Full Text] [Related]
27. Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions.
Kleynerman A; Rybova J; Faber ML; McKillop WM; Levade T; Medin JA
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830643
[TBL] [Abstract][Full Text] [Related]
28. Spinal muscular atrophy with progressive myoclonic epilepsy: report of new cases and review of the literature.
Haliloglu G; Chattopadhyay A; Skorodis L; Manzur A; Mercuri E; Talim B; Akçören Z; Renda Y; Muntoni F; Topaloğlu H
Neuropediatrics; 2002 Dec; 33(6):314-9. PubMed ID: 12571787
[TBL] [Abstract][Full Text] [Related]
29. [Pathogenic gene variants and clinical phenotype features of 26 children with progressive myoclonic epilepsy].
Zhang J; Zhang YH; Chen JY; Ji TY; Yang ZX; Yang XL; Sun W; Zhang LP; Wu XR
Zhonghua Er Ke Za Zhi; 2019 Jun; 57(6):458-464. PubMed ID: 31216804
[No Abstract] [Full Text] [Related]
30. A case of ASAH1-related pure SMA evolving into adult-onset Farber disease.
Puma A; Ezaru A; Cavalli M; Villa L; Torre F; Biancalana V; Levade T; Grecu N; Sacconi S
Clin Genet; 2021 Aug; 100(2):234-235. PubMed ID: 34240417
[No Abstract] [Full Text] [Related]
31. A novel case report of spinal muscular atrophy with progressive myoclonic epilepsy from Iran.
Shervin Badv R; Nilipour Y; Rahimi-Dehgolan S; Rashidi-Nezhad A; Ghahvechi Akbari M
Int Med Case Rep J; 2019; 12():155-159. PubMed ID: 31213928
[TBL] [Abstract][Full Text] [Related]
32. Atypical presentation of infantile-onset farber disease with novel ASAH1 mutations.
Kim SY; Choi SA; Lee S; Lee JS; Hong CR; Lim BC; Kang HJ; Kim KJ; Park SH; Choi M; Chae JH
Am J Med Genet A; 2016 Nov; 170(11):3023-3027. PubMed ID: 27411168
[TBL] [Abstract][Full Text] [Related]
33. A new case of SMA phenotype without epilepsy due to biallelic variants in ASAH1.
Ame van der Beek N; Nelson I; Froissart R; Levade T; Garcia V; Lacene E; Boland A; Masson C; Romero NB; Stojkovic T; Bonne G; Béhin A
Eur J Hum Genet; 2019 Mar; 27(3):337-339. PubMed ID: 30291339
[No Abstract] [Full Text] [Related]
34. Structural basis for the activation of acid ceramidase.
Gebai A; Gorelik A; Li Z; Illes K; Nagar B
Nat Commun; 2018 Apr; 9(1):1621. PubMed ID: 29692406
[TBL] [Abstract][Full Text] [Related]
35. A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy.
Monani UR; Pastore MT; Gavrilina TO; Jablonka S; Le TT; Andreassi C; DiCocco JM; Lorson C; Androphy EJ; Sendtner M; Podell M; Burghes AH
J Cell Biol; 2003 Jan; 160(1):41-52. PubMed ID: 12515823
[TBL] [Abstract][Full Text] [Related]
36. Identification of ASAH1 as a susceptibility gene for familial keloids.
Santos-Cortez RLP; Hu Y; Sun F; Benahmed-Miniuk F; Tao J; Kanaujiya JK; Ademola S; Fadiora S; Odesina V; Nickerson DA; Bamshad MJ; Olaitan PB; Oluwatosin OM; Leal SM; Reichenberger EJ
Eur J Hum Genet; 2017 Oct; 25(10):1155-1161. PubMed ID: 28905881
[TBL] [Abstract][Full Text] [Related]
37. Zebrafish acid ceramidase: Expression in Pichia pastoris GS115and biochemical characterization.
Rajput VB; Karthikeyan M; Ramasamy S
Int J Biol Macromol; 2019 Feb; 122():587-593. PubMed ID: 30399382
[TBL] [Abstract][Full Text] [Related]
38. Spinal Muscular Atrophy and Progressive Myoclonic Epilepsy: A Rare Association.
Radhakrishnan DM; Shree R; Madhaw G; Manchanda R; Mahadevan A; Kumar N
J Neurosci Rural Pract; 2021 Jan; 12(1):210-212. PubMed ID: 33531786
[TBL] [Abstract][Full Text] [Related]
39. Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy.
Schuchman EH
Biochim Biophys Acta; 2016 Sep; 1862(9):1459-71. PubMed ID: 27155573
[TBL] [Abstract][Full Text] [Related]
40. Novel V97G ASAH1 mutation found in Farber disease patients: unique appearance of the disease with an intermediate severity, and marked early involvement of central and peripheral nervous system.
Chedrawi AK; Al-Hassnan ZN; Al-Muhaizea M; Colak D; Al-Younes B; Albakheet A; Tulba S; Kaya N
Brain Dev; 2012 May; 34(5):400-4. PubMed ID: 21893389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
